All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Priority Review to First-Line T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

September 24th 2025

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

IIT Madras partners with LSU Health New Orleans, US, to Accelerate Global Health Innovation

September 24th 2025

The collaboration blends LSU Health New Orleans’s robust research capabilities with IIT Madras’ technology innovation to drive global health impact.

Advancements in Prostate Cancer Imaging, Minimally Invasive Approaches Require Cohesive Screening Recommendations to Optimize Patient Outcomes

September 24th 2025

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Lifileucel Shows Durable 5-Year Benefit in Advanced Melanoma Resistant to Immune Checkpoint Inhibitors

September 24th 2025

Theresa Medina, MD, discusses 5-year C-144-01 results with lifileucel in advanced melanoma.

Personalized Approaches Are Emerging for GVHD in Hematologic Malignancies

September 24th 2025

A panel of hematologic cancer experts discusses data on GVHD management from the 2025 SOHO Annual Meeting.

Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Is Crucial for Endometrial Cancer Risk Reduction

September 23rd 2025

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.

Pirtobrutinib Expands Potential Second-Line Options in CLL

September 23rd 2025

Asad Dean, MD, discusses the evolving role of pirtobrutinib in chronic lymphocytic leukemia.

Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition

September 23rd 2025

OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.

IberDd Demonstrates Positive Topline Efficacy in Relapsed/Refractory Multiple Myeloma

September 23rd 2025

IberDd improved MRD negativity rates vs DVd in patients with relapsed/refractory multiple myeloma.

Yale Cancer Center Names Tracy Battaglia MD, MPH, as New Leader of Community Outreach and Engagement

September 23rd 2025

Tracy Battaglia, MD, MPH, joined Yale Cancer Center’s Community Outreach and Engagement as associate director.

INESSS Issues Positive Recommendation for the Reimbursement of Subcutaneous Nivolumab Across Solid Tumor Indications

September 23rd 2025

INESSS has issued a positive recommendation for the reimbursement of subcutaneous nivolumab across all Health Canada–authorized solid tumor indications.

Linvoseltamab Adds Highly Effective Option in Later-Line Multiple Myeloma

September 23rd 2025

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Selumetinib Earns Positive CHMP Opinion for Adult NF1-Associated PNs

September 23rd 2025

CHMP has recommended the approval of selumetinib for symptomatic, inoperable plexiform neurofibromas (PNs) in adult neurofibromatosis type 1.

Post–CAR T-Cell Monitoring Optimization Improves Access and Safety for Patients With B-Cell Malignancies

September 23rd 2025

Manali Kamdar, MD, discusses advances with CAR T-cell therapy in B-cell malignancies and the monitoring needs for CRS and ICANS that affect patient access.

Poll: Vote on the Top Lung, GU Cancer Abstracts to Watch at ESMO 2025

September 22nd 2025

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

Radioligand Therapy Sequencing, Novel Targets Continue to Shape Prostate Cancer Care and Research

September 22nd 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the evolving role of radioligand therapies for the treatment of PSMA-positive prostate cancer.

Real-World Data Show Hematologic Responses With Pacritinib in Myelofibrosis With Anemia

September 22nd 2025

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

September 22nd 2025

Patients with lung cancer who take GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes management—fare better than those who don’t.

Vorasidenib Nets European Approval in IDH1/2-Mutated Grade 2 Glioma

September 22nd 2025

Vorasidenib has been approved by the European Commission for IDH1/2-mutated grade 2 glioma.

Giredestrant Plus Everolimus Meets Coprimary PFS End Points in Post–CDK Inhibitor ER+/HER2– Breast Cancer

September 22nd 2025

Giredestrant plus everolimus improved PFS vs SOC endocrine therapy plus everolimus in CDK4/6 inhibitor–pretreated, ER-positive breast cancer.